Outcomes of endoscopic transpapillary gallbladder stenting (ETGS) in gallstones with acute cholangitis patients whose cholecystectomy are deferred: a randomized controlled trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20240624004

Enrollment

176

Registered

2024-06-24

Start date

2024-06-25

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gallstone-associated acute cholangitis Gallstone, Cholangitis, Transpapillary gallbladder stenting

Interventions

Endoscopic transpapillary gallbladder stentint (ETGS) is a stent that inserted to gallbladder through transpapillary, which have one site in gallbladder and another site in second part duodenum. The s

Active Comparator Procedure/Surgery,No Intervention No treatment

Endoscopic transpapillary gallbladder stenting (ETGS),no endoscopic transpapillary gallbladder stent

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Age >/= 18 years old - Gallstone with acute cholangitis patients - Evaluated by surgical team and cholecystectomy is deferred

Exclusion criteria

Exclusion criteria: - Acute cholecystitis - Acute biliary pancreatitis - Hemodynamic unstable - Uncontrolled coagulopathy - Schedule for cholecystectomy within 3 months - Previous ERCP - Refuse to provide informed consent

Design outcomes

Primary

Measure	Time frame
Pancreatobiliary events 3 months diagnosis by physician	—

Secondary

Measure	Time frame
technical success rate at the end of the intervention by fluoroscopy,clinical success rate 72 hours Proportion of patients who have resolution of symptoms, liver function test and leukocytosis,procedural related adverse events 2 weeks Proportion of patients who develop adverse events after procedure,rate of pancreatobiliary events during 6-month follow up 6 months Proportion of patients who develop pancreatobiliary events during 6-month follow up	—

Measure

Time frame

technical success rate at the end of the intervention by fluoroscopy,clinical success rate 72 hours Proportion of patients who have resolution of symptoms, liver function test and leukocytosis,procedural related adverse events 2 weeks Proportion of patients who develop adverse events after procedure,rate of pancreatobiliary events during 6-month follow up 6 months Proportion of patients who develop pancreatobiliary events during 6-month follow up

—

Countries

Thailand

Contacts

Public ContactNatsida Rathanaviriyachai

Division of gastroenterology, Department of medicine, Faculty of medicine, Chulalongkorn University

natsida.boe@gmail.com022564265

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Apr 4, 2026